Insider Monkey
Merck & Company Inc. (new) News
Latest updates and market news for MRK
16 news
Jan 18 - Jan 24, 2026
Page 1
Barrons.com
AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.
➖
AI Sentiment
Neutral
4/10
Barrons.com
These Stocks Are Today’s Movers: Intel, GE Aerospace, Moderna, Abbott, Arista Networks, Mobileye, McCormick, and More
➖
AI Sentiment
Neutral
5/10
Zacks
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors
📈
AI Sentiment
Highly Positive
8/10
Zacks
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
📈
AI Sentiment
Highly Positive
10/10
Insider Monkey
Jim Cramer Highlights “Takeover Interest” in Revolution Medicines
📊
AI Sentiment
Positive
7/10
MT Newswires
TD Cowen Adjusts Price Target on Merck to $120 From $100, Maintains Hold Rating
📊
AI Sentiment
Positive
7/10
MT Newswires
Leerink Partners Adjusts Price Target on Merck to $124 From $114, Maintains Outperform Rating
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Is Merck’s Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK?
📊
AI Sentiment
Positive
7/10
GlobeNewswire
LaunchDarkly Expands Leadership Team in Response to Accelerated Growth and AI Tailwinds
📈
AI Sentiment
Highly Positive
10/10
MT Newswires
Moderna, Merck's Skin Cancer Therapy Shows 49% Lower Risk of Cancer in Mid-Stage Study
➖
AI Sentiment
Neutral
5/10
Barrons.com
This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.
📈
AI Sentiment
Highly Positive
8/10
ACCESS Newswire
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
📈
AI Sentiment
Highly Positive
9/10
Share this news page